Biologic activities of trail in soft tissue sarcoma cell lines: induction of apoptosis and interaction with cytotoxic agents (original) (raw)
Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL
Gerald Atkins
Journal of orthopaedic surgery (Hong Kong), 2001
View PDFchevron_right
Trail induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines
Sandra Tomek
European Journal of Cancer, 2001
View PDFchevron_right
TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo
Andrea Hayes-Jordan
Clinical Cancer Research, 2010
View PDFchevron_right
Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin
David Findlay
International Journal of Oncology, 2004
View PDFchevron_right
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial
Wolfgang Koestler
European Journal of Cancer, 2001
View PDFchevron_right
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail-induced apoptosis
David Findlay
International Journal of Cancer, 2002
View PDFchevron_right
Appraising the Current Role of Chemotherapy for the Treatment of Sarcoma
David D’Adamo
Seminars in Oncology, 2011
View PDFchevron_right
A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma
Shail Verma
Sarcoma, 1998
View PDFchevron_right
The Use of Chemotherapy in Soft-Tissue Sarcomas
LUIS PADILLA
View PDFchevron_right
The role of chemotherapy in the treatment of bone and soft tissue sarcomas
Martin Malawer
Current Orthopaedics, 2005
View PDFchevron_right
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study
ANDRES FELIPE FRANCO POVEDA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
View PDFchevron_right
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view
R. Somers
Critical Reviews in Oncology/Hematology, 1995
View PDFchevron_right
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Claudia Lebedinsky
Clinical Cancer Research, 2008
View PDFchevron_right
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment
Dominique Heymann, Stéphane Téletchéa
American journal of cancer research, 2012
View PDFchevron_right
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Arthur Staddon
Journal of Clinical Oncology, 2012
View PDFchevron_right
Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma
Jared Harwood
Orthopedic Clinics of North America, 2015
View PDFchevron_right
Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?
isabelle ray-coquard
European Journal of Cancer, 2011
View PDFchevron_right
Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy
Mary Keohan
Cancer, 2006
View PDFchevron_right
The Importance of Being Dead: Cell Death Mechanisms Assessment in Anti-Sarcoma Therapy
Santiago Rello-Varona
Frontiers in Oncology, 2015
View PDFchevron_right
The promise of TRAIL—potential and risks of a novel anticancer therapy
Tom Ganten
2007
View PDFchevron_right
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Robin L Jones
Medical oncology (Northwood, London, England), 2018
View PDFchevron_right
“Metronomic” chemotherapy in advanced soft tissue sarcomas
Eberhard Stoeckle
Cancer Chemotherapy and Pharmacology, 2010
View PDFchevron_right
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma
I. Poller
Cancer, 2000
View PDFchevron_right
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
Wolter Oosterhuis, Ian Judson
European Journal of Cancer, 2003
View PDFchevron_right
Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
Pancras C . W . Hogendoorn
Journal of Clinical Oncology, 2007
View PDFchevron_right